Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

References

• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, David K, Grainger DL, et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 1999;60(Suppl. 19):14-19
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl.):1-56
   Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
   PubMed Web of Science ®Google Scholar
• Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Anderson CM, Reiss DJ, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Environmental–Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Arch Gen Psychiatry 1991;48:340-7
   PubMed Web of Science ®Google Scholar
• Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 2006;11(12 Suppl. 14):1-7; quiz 7-8
   Web of Science ®Google Scholar
• Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl. 16):18-23
   PubMed Web of Science ®Google Scholar
• McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(Suppl. 5):15-18
   PubMed Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Andersen SW, et al. 160 week interim results from an open-label extension trial of olanzapin long-acting injection [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl. 1):151
   Google Scholar
• Gulliver A, McDonnell DP, Sorsaburu S, et al. Injection-related adverse events observed with olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl. 1):152
   Google Scholar
• Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
   PubMed Web of Science ®Google Scholar
• Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-9
   PubMed Web of Science ®Google Scholar
• Marino J, Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 2008;28:1283-98
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Samtani M, et al. Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: Results of two randomized double-blind studies and population pharmacokinetic simulations. Presented at the American Society for Pharmacology and Therapeutics. Scottsdale, AZ, USA, December 7–11 2008
   Google Scholar
• Simpson G, Pandina G, Lane R, et al. A randomized, double-blind, comparative study of flexible doses of paliperidone palmitate and risperidone long-acting therapy in patients with schizophrenia. Presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 6–10, 2009
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 2002;159:1534-40
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-35
   PubMed Web of Science ®Google Scholar
• Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:1218-25
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Wu B, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006;39:135-41
   PubMed Web of Science ®Google Scholar
• Arango C, Bombin I, Gonzalez-Salvador T, et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006;21:34-40
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17
   PubMed Web of Science ®Google Scholar
• Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 2008;11:48-56
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [Erratum]. N Engl J Med 2010;363:1092-3
   Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(Suppl. 1):75-89
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resource Alloc 2009;7:4
   PubMedGoogle Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
   PubMed Web of Science ®Google Scholar
• Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003;64:898-906
   PubMed Web of Science ®Google Scholar
• Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821-5
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Stauffer VL, Liu-Seifert H, et al. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 2007;27:252-8
   PubMed Web of Science ®Google Scholar
• Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-53
   PubMed Web of Science ®Google Scholar
• Dossenbach M, Erol A, el Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004;65:312-21
   PubMed Web of Science ®Google Scholar
• Zyprexa Relprevv Prescribing Information. Prescribing Information, 2009
   Google Scholar
• AWP/NWP cost of antipsychotics. Analysource Data, 2009. Available at: www.Analysource.com [Last accessed 3 February 2010]
   Google Scholar
• Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010;64:216-39
   PubMed Web of Science ®Google Scholar
• Average Medicare 2008 Reimbursement for Common Procedural Terminology Code 90772 (therapeutic, prophylactic or diagnostic injection). Centers for Medicare and Medicaid Services. Available at: www.http://cms.hhs.gov/ [Last accessed 3 February 2010]
   Google Scholar
• Leslie DL, Rosenheck RA. Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes. Psychiatr Serv 2005;56:803-9
   PubMed Web of Science ®Google Scholar
• drugstore.com. Available at: www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00378654091&trx=1Z5006 [3 February 2010]
   Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004;7:569-84
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224
   PubMed Web of Science ®Google Scholar
• Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007;58:482-8
   PubMed Web of Science ®Google Scholar
• West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008;34:995-1001
   PubMed Web of Science ®Google Scholar
• Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007;191:14-22
   PubMed Web of Science ®Google Scholar
• Leeuwenkamp O, Morlock R, Bell C, et al. Costs and outcomes of atypical antipsychotics for the treatment of acute schizophrenia [abstract]. Value Health 2008;98:167
   Google Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007;61:1979-88
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-9
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004;3:11
   PubMedGoogle Scholar
• Dossenbach M, Arango-Davila C, Silva IH, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005;66:1021-30
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006;26:571-8
   PubMed Web of Science ®Google Scholar
• Stauffer V, Ascher-Svanum H, Liu L, et al. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry 2009;9:13
   PubMed Web of Science ®Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6
   PubMedGoogle Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
   PubMed Web of Science ®Google Scholar
• Risperdal Consta Prescribing Information. Prescribing Information. Titusville, NJ: Janssen Pharmaceutical Ltd, 2009
   Google Scholar
• Haloperidol Decanoate Prescribing Information. Prescribing Information. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc., 2009
   Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74
   PubMed Web of Science ®Google Scholar
• Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312-20
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005;6:129-37
   PubMedGoogle Scholar
• HCUP Nationwide Inpatient Sample (NIS), 2004. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality. Available at: http://hcupnet.ahrq.gov/HCUPnet.jsp [Last accessed 3 February 2010]
   Google Scholar